Eagle's Eye View: Your Weekly CV Update From ACC.org LAAO and the Watchman FLX; HF Care in Private Equity Hospitals; Long-term Outcomes in TR and Mitral Valve-in-Valve Replacement
6 snips
Jun 18, 2025 Discover the latest advancements in cardiac procedures, including the lower risk of major adverse events with the new Watchman 2.4 device for left atrial appendage occlusion. Learn about the intriguing dynamics of heart failure care in private equity hospitals and how these settings are reshaping treatment. Plus, delve into the long-term outcomes for patients with tricuspid regurgitation undergoing mitral valve-in-valve replacements, revealing important prognostic insights.
AI Snips
Chapters
Transcript
Episode notes
Watchman FLX Improves Stroke Outcomes
- The Watchman FLX device cuts ischemic stroke risk by 18% over one year versus the prior version.
- It also reduces peri-device leaks significantly, improving outcomes for patients avoiding anticoagulation.
Private Equity Impacts Heart Failure Care
- Private equity acquisition of hospitals raises cardiac catheterization rates despite lower patient risk.
- African-American heart failure patients face increased transfers post-acquisition, highlighting care disparities.
Tricuspid Regurgitation Affects Mortality
- Severe tricuspid regurgitation (TR) at mitral valve-in-valve replacement predicts higher 3-year mortality.
- TR often improves post-procedure, correlating with better survival, but targeted TR interventions need more study.